With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.

Jimmy Vielkind is a former reporter for The Wall Street Journal, where he covered New York, New Jersey and Connecticut. His stories often looked at the impact of state policies on the tristate ...

The Wall Street Journal’s Economic Forecasting Survey has helped readers better understand the direction of the U.S. economy ...

Survey finds tariffs, tax cuts and immigration policy could weigh on price outlook for next two years.

Voter support many of his second-term goals. They are just not on board with all the ways he wants to accomplish them.

Kohl's has been having a rough go in recent years, but that hasn't stopped it from offering a stellar senior discount one day ...

Collin Eaton writes about the largest American oil companies and global energy issues in The Wall Street Journal's Houston bureau. Collin joined the Journal in early 2020, a few weeks before the ...

The president touted his achievements and outlined his concerns for the future of America.

Twitter's stock price rose 27 percent once Musk belatedly disclosed his stake, the lawsuit said. "During the period that Musk ...

BlackRock and JPMorgan Chase are two of the most closely watched succession sagas on Wall Street. With full-year earnings ...

A vision for the future of retail is under way at this city’s Burlington clothing store. The one-year-old shop is nearly 80% ...

Walgreens improving pharmacy business and comments from the company’s CEO are convincing Wall Street that the drugstore won't ...